GLP-1 receptor agonists like semaglutide are creating an unexpected cosmetic consequence: accelerated facial aging through volume loss, skin laxity, and wrinkle formation during rapid weight reduction. The phenomenon has prompted increased demand for dermal fillers, biostimulators, and skin-tightening procedures to counteract these effects. This represents a fascinating collision between metabolic medicine and aesthetic dermatology. The rapid fat loss these medications produce appears to disproportionately affect facial subcutaneous tissue, which normally provides structural support and youthful contours. Unlike gradual weight loss where skin can adapt over time, the accelerated pace of GLP-1-induced weight reduction may outpace the skin's natural remodeling capacity. The aesthetic industry is scrambling to develop protocols specifically for this growing patient population, but the underlying mechanisms remain poorly understood. This creates both opportunity and risk — while cosmetic interventions can address the visible effects, we lack long-term data on optimal timing and techniques. The emergence of "semaglutide face" as a recognized phenomenon highlights how breakthrough medical treatments can create entirely new categories of aesthetic concerns, requiring interdisciplinary approaches between endocrinologists and dermatologists.